← All trials
NCT06385119
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2024
- Primary completion
- Oct 31, 2024
- Completion date
- Nov 25, 2024
- First posted
- Apr 25, 2024
- Last posted
- May 10, 2024
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Novellus TherapeuticsLead sponsor
- Novellus TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.